| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| CAVA GROUP, INC. | Director | Common Stock | 9,507,990 | $1,275,306,699 | $134.13 | 18 Nov 2024 | Direct |
| LEXICON PHARMACEUTICALS, INC. | Director, 10%+ Owner | Common Stock | 136,180,481 | $356,792,860 | $2.62 | 10 May 2024 | Indirect |
| LEXICON PHARMACEUTICALS, INC. | Director, 10%+ Owner | Series A Convertible Preferred Stock | 0 | $0 | $108.50 | 10 May 2024 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CAVA | CAVA GROUP, INC. | 18 Nov 2024 | 1 | -$1,073,040,000 | 4 | Director | 20 Nov 2024, 16:30 |
| CAVA | CAVA GROUP, INC. | 26 Aug 2024 | 1 | -$698,160,000 | 4 | Director, 10%+ Owner | 28 Aug 2024, 16:30 |
| CAVA | CAVA GROUP, INC. | 05 Jun 2024 | 1 | -$261,750,000 | 4 | Director, 10%+ Owner | 07 Jun 2024, 16:30 |
| LXRX | LEXICON PHARMACEUTICALS, INC. | 10 May 2024 | 3 | +$124,875,037 | 4 | Director, 10%+ Owner | 14 May 2024, 17:17 |
| CAVA | CAVA GROUP, INC. | 21 Mar 2024 | 1 | -$132,500,000 | 4 | Director, 10%+ Owner | 25 Mar 2024, 16:15 |
| LXRX | LEXICON PHARMACEUTICALS, INC. | 13 Mar 2024 | 1 | +$124,875,037 | 4 | Director, 10%+ Owner | 13 Mar 2024, 21:22 |
| CAVA | CAVA GROUP, INC. | 27 Feb 2024 | 1 | -$187,600,000 | 4 | Director, 10%+ Owner | 29 Feb 2024, 16:16 |
| CAVA | CAVA GROUP, INC. | 20 Jun 2023 | 12 | $0 | 4 | Director, 10%+ Owner | 22 Jun 2023, 16:30 |
| CAVA | CAVA GROUP, INC. | 15 Jun 2023 | 0 | $0 | 3 | Director, 10%+ Owner | 15 Jun 2023, 16:30 |
| LXRX | LEXICON PHARMACEUTICALS, INC. | 05 Jun 2023 | 1 | +$72,215,130 | 4 | Director, 10%+ Owner | 05 Jun 2023, 16:46 |
| LXRX | LEXICON PHARMACEUTICALS, INC. | 05 Aug 2022 | 1 | +$6,065,175 | 4 | Director, 10%+ Owner | 09 Aug 2022, 16:46 |
| LXRX | LEXICON PHARMACEUTICALS, INC. | 01 Aug 2022 | 1 | +$40,434,500 | 4 | Director, 10%+ Owner | 01 Aug 2022, 16:15 |